Indian Journal of Cancer
Home  ICS  Feedback Subscribe Top cited articles Login 
Users Online :1570
Small font sizeDefault font sizeIncrease font size
Read this article

 


    Article Cited by others

ORIGINAL ARTICLE

Presence of CD3+ tumor infiltrating lymphocytes is significantly associated with good prognosis in infiltrating ductal carcinoma of breast

Rathore A S, Kumar S, Konwar R, Srivastava A N, Makker A, Goel M M

Year : 2013| Volume: 50| Issue : 3 | Page no: 239-244

   This article has been cited by
 
1 Prognostic Value of the Neo-Immunoscore in Renal Cell Carcinoma
Congfang Guo,Hua Zhao,Yu Wang,Shuai Bai,Zizhong Yang,Feng Wei,Xiubao Ren
Frontiers in Oncology. 2019; 9
[Pubmed]  [Google Scholar] [DOI]
2 Tumor infiltrating lymphocytes in early breast cancer
Giancarlo Pruneri,Andrea Vingiani,Carsten Denkert
The Breast. 2018; 37: 207
[Pubmed]  [Google Scholar] [DOI]
3 In situ localization of tumor cells associated with the epithelial-mesenchymal transition marker Snail and the prognostic impact of lymphocytes in the tumor microenvironment in invasive ductal breast cancer
Ibrahim Alkatout,Friederike Hübner,Antonia Wenners,Jürgen Hedderich,Meike Wiedermann,Cristina Sánchez,Christoph Röcken,Micaela Mathiak,Nicolai Maass,Wolfram Klapper
Experimental and Molecular Pathology. 2017; 102(2): 268
[Pubmed]  [Google Scholar] [DOI]
4 Predictive factors of the tumor immunological microenvironment for long-term follow-up in early stage breast cancer
Mina Okabe,Uhi Toh,Nobutaka Iwakuma,Shuko Saku,Momoko Akashi,Yuko Kimitsuki,Naoko Seki,Akihiko Kawahara,Etsuyo Ogo,Kyogo Itoh,Yoshito Akagi
Cancer Science. 2017; 108(1): 81
[Pubmed]  [Google Scholar] [DOI]
5 Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study
Gloria Romagnoli,Meike Wiedermann,Friederike Hübner,Antonia Wenners,Micaela Mathiak,Christoph Röcken,Nicolai Maass,Wolfram Klapper,Ibrahim Alkatout
International Journal of Molecular Sciences. 2017; 18(9): 1936
[Pubmed]  [Google Scholar] [DOI]
6 Prognostic Factors for Breast Cancer: an Immunomorphological Update
Luca Roncati,Giuseppe Barbolini,Federico Piacentini,Francesco Piscioli,Teresa Pusiol,Antonio Maiorana
Pathology & Oncology Research. 2016; 22(3): 449
[Pubmed]  [Google Scholar] [DOI]
7 The Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Systematic Review and Meta-Analysis
Yan Mao,Qing Qu,Xiaosong Chen,Ou Huang,Jiayi Wu,Kunwei Shen,Elda Tagliabue
PLOS ONE. 2016; 11(4): e0152500
[Pubmed]  [Google Scholar] [DOI]
8 Prognostic and predictive value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis
X. Yu,Z. Zhang,Z. Wang,P. Wu,F. Qiu,J. Huang
Clinical and Translational Oncology. 2016; 18(5): 497
[Pubmed]  [Google Scholar] [DOI]
9 CD8+ tumor infiltrating lymphocytes strongly correlate with molecular subtype and clinico-pathological characteristics in breast cancer patients from Sudan
Mahmoud Mohamed,Hina Sarwath,Nada Salih,Devendra Bansal,Prem Chandra,Nazik E. Husain,Lotfi Chouchane,Ali A. Sultan,Shahinaz Bedri
Translational Medicine Communications. 2016; 1(1)
[Pubmed]  [Google Scholar] [DOI]
10 Tumor infiltrating CD8+T lymphocyte count is independent of tumor TLR9 status in treatment naïve triple negative breast cancer and renal cell carcinoma
Mikko Mella,Joonas H Kauppila,Peeter Karihtala,Petri Lehenkari,Arja Jukkola-Vuorinen,Ylermi Soini,Päivi Auvinen,Markku H Vaarala,Hanna Ronkainen,Saila Kauppila,Kirsi-Maria Haapasaari,Katri S Vuopala,Katri S Selander
OncoImmunology. 2015; 4(6): e1002726
[Pubmed]  [Google Scholar] [DOI]
11 Tumor-Infiltrating Lymphocytes in Breast Cancer: Ready for Prime Time?
Alberto Ocaña,Laura Diez-Gónzález,Encarna Adrover,Antonio Fernández-Aramburo,Atanasio Pandiella,Eitan Amir
Journal of Clinical Oncology. 2015; 33(11): 1298
[Pubmed]  [Google Scholar] [DOI]

 

  Site Map | What's new | Copyright and Disclaimer
  Online since 1st April '07
  © 2007 - Indian Journal of Cancer | Published by Wolters Kluwer - Medknow